Oncotarget | MK256 a Novel CDK8 Inhibitor With Potent Antitumor Activity in AML Through Downregulation of STAT Pathway
November 10, 2022
In summary, our study shows that MK256, a potent and selective CDK8 inhibitor, is an effective negative STAT pathway regulator both in vitro and in vivo in AML.”BUFFALO, NY-... read more
